A 46-Year-Old Woman with Primary Infertility and a Diagnosis of Microcystic Stromal Tumor of the Ovary Confirmed by Histology and Gene Sequencing: A Case Report and Review of the Literature

Maria A. Arafah
Layla AlBreacan
Khalid Akkour
Suliman Alomar

Patient: Female, 46-year-old
Final Diagnosis: Microcystic stromal tumor of the ovary
Symptoms: Abdominal pain • vaginal bleeding
Medication: —
Clinical Procedure: —
Specialty: Pathology

Objective: Rare disease

Background: Microcystic stromal tumor (MCST) of the ovary is a rare entity with distinct pathological and molecular features. However, a lack of awareness of ovarian MCST can lead to delayed diagnosis or misdiagnosis. We present a case of ovarian MCST and review all previously reported cases and discuss their clinical and pathological characteristics.

Case Report: A 46-year-old woman with primary infertility due to polycystic ovary syndrome presented with bleeding and pain. Radiological images showed a complex solid and cystic adnexal mass. Microscopically, the tumor was lobulated with cellular regions separated by fibrous plaques and small anastomosing cysts, consistent with an ovarian MCST. The tumor cells showed positive staining for vimentin, CAM 5.2, CD10, β-Catenin, CD99, and cyclin D1. Genetic sequencing showed a point mutation in the CTNNB1 gene, with no mutations in the APC, BRCA1, and BRCA2 genes. The patient underwent surgery and was disease-free at 24 months after her initial diagnosis.

Conclusions: The diagnosis of ovarian MCST should consider the differential diagnosis of cystic tumors of the ovary. Further research is encouraged to elucidate the various molecular pathways involved in the pathogenesis of this tumor and to determine its optimal treatment and long-term prognosis.

Keywords: Ovarian Neoplasms • CTNNB1 Protein, Human • Genes, APC

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/933528

Indexed in: [PMC] [PubMed] [Emerging Sources Citation Index (ESCI)] [Web of Science by Clarivate]

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
**Background**

Ovarian microcystic stromal tumor (MCST) was first reported in 2009 by Irving and Young [1] and was then included as a pure ovarian stromal tumor in the 2014 World Health Organization Classification of Tumors of the Female Reproductive Organs [2]. Ovarian MCSTs have distinctive morphological features, including microcysts and cellular lobules with an intervening fibrous, or sometimes hyalinized stroma. They lack the morphological features of other sex cord-stromal tumors and do not show any germ cell, teratomatous, or epithelial elements. They are also characterized by unique immunohistochemical and molecular profiles [1,3].

Fewer than 60 cases of ovarian MCSTs have been reported to date [1,4-27] all of which were in adults, had a mean size of <10 cm, and had benign outcomes, except for a case of pelvic recurrence [21]. We present a case of an ovarian MCST in a 46-year-old woman with primary infertility due to polycystic ovary syndrome. We also discuss the histopathological, radiological, immunophenotypical, and molecular features of this tumor and review all previously reported cases.

**Case Report**

A 46-year-old woman presented with intermittent vaginal bleeding and moderate abdominal pain for 3 days. She had a history of primary infertility and polycystic ovaries, for which she received various fertility regimens and underwent a series of ultrasound imaging for 3 years. She also underwent a myomectomy for a uterine fibroid 6 years before her presentation. She had no family history of malignant tumors. The patient had a body mass index of 36.85 kg/m² and a slightly tender abdomen with no palpable inguinal lymph nodes on physical examination. Her vital signs were stable upon admission, and all laboratory investigations were within normal limits, including a complete blood count, coagulation profile, urea and electrolyte panel, renal and liver function tests, and tumor markers (CA 125, CA 15-3, CA 19-9, CEA, AFP, and β-HCG).

Pelvic ultrasound showed a large complex left adnexal mass, measuring 15.3×12.3×10.6 cm, with cystic and solid components. Two small intramural fibroids were also noted. Magnetic resonance imaging (MRI) of the pelvis showed a complex multiloculated cystic mass with few enhancing solid areas, measuring 17×15×9 cm (**Figure 1A, 1B**). The uterus was displaced with multiple intramural fibroids and showed diffuse adenomyosis. A large area of loculated fluid was also seen in the pouch of Douglas, measuring 7×6.5×7.5 cm, displacing the rectum posteriorly. Radiologically, these findings were likely to represent a malignant epithelial ovarian neoplasm. The patient was scheduled for surgery with an intraoperative consultation, which suggested at the time a sex cord-stromal tumor. The patient underwent an open left salpingo-oophorectomy, infra-colic omentectomy, bilateral peritoneal biopsies, left pelvic lymph nodes dissection, and an appendectomy. Fluid from the pouch of Douglas was taken for cytological examination and was negative for malignant cells.

**Figure 1.** Magnetic resonance imaging of the pelvis with intravenous contrast showing a large complex multiloculated left adnexal mass. (A) A sagittal T2-weighted image and (B) an axial T2-weighted image.
Macroscopically, the ovarian mass weighed 935 g and measured 17.5×16×6.4 cm. It was firm with a smooth outer surface. Serial slicing showed a complex partially solid and partially cystic mass. The cystic areas were filled with a clear fluid, while the solid areas were pale tan and homogenous. No papillary projections were seen.

Microscopically, the tumor was lobulated with cellular regions separated by fibrous plaques (Figure 2A) and small anastomosing cysts (Figure 2B). The neoplastic cells were round with pale finely granular eosinophilic cytoplasm and round to oval nuclei (Figure 2C, 2D). Small nucleoli were occasionally noted, and mitoses were absent. The other specimens were histologically unremarkable.

The tumor cells showed positive staining for vimentin, CAM 5.2, CD10, β-Catenin, CD99 (paranuclear dot-like pattern), and cyclin D1 (Figure 3A-3F). Around 5% to 10% of cells showed weak nuclear positivity for progesterone receptors. All other markers were negative, including inhibin, calretinin, PLAP, EMA, cytokeratin 20, cytokeratin 7, melan A, chromogranin, synaptophysin, AFP, WT-1, and estrogen receptors. The microscopic findings and immunohistochemical results were in keeping with an MCST of the ovary. Genetic sequencing showed a point mutation in the CTNNB1 gene. There were no mutations detected in APC, BRCA1, and BRCA2 genes.

The patient was discharged in good health on the third day after surgery, and she was disease-free 24 months after her initial diagnosis. She is still following up with her gynecologist for primary infertility and general surgery for a future sleeve gastrectomy. A written informed consent for patient information and images to be published was obtained from the patient.
Figure 3. A panel of immunohistochemical stains. (A) CD99 shows a paranuclear dot-like pattern of staining in tumor cells. Tumor cells are positive for (B) CAM 5.2, and (C) CD10. They also show positive nuclear staining for (D) \( \beta \)-Catenin, (E) cyclin D1, and focally for (F) progesterone receptors (immunohistochemical staining, ×200).
### Discussion

The first detailed description of an ovarian MCST was published in 2009 by Irving and Young, based on 16 uncategorized tumors of the ovary [1]. In 2011, Maeda et al reported β-catenin nuclear expression and CTNNB1 point mutations in 2 cases of ovarian MCST, proposing that the Wnt/β-catenin pathway contributes to the pathogenesis of this tumor [4]. In 2014, ovarian MCST was added as a pure ovarian stromal tumor to the WHO Classification of Tumors of the Female Reproductive Organs [2]. Yang et al then described the ultrastructural features of these tumors and showed an aberrant nuclear expression of the p27 protein, suggesting a simultaneous dysregulation of the p27kip1 tumor suppressor gene [5]. In 2015, Lee et al reported an ovarian MCST in a patient with familial adenomatous polyposis. The tumor displayed a somatic mutation in the APC gene (exon 11) and no mutations in the CTNNB1 gene [9]. The pure stromal origin of ovarian MCST was later supported by Meurgeon et al, who reported the lack of FOXL2 and DICER1 mutations in 3 cases [18].

A total of 56 cases of ovarian MCST have been reported to date (Table 1). All cases were in adults, with a mean age of 44 years (range: 23–71 years) [1,4–27]. All cases were unilateral, with more on the left side, had a mean size of <10 cm, and lacked hormonal manifestations [1,4–27]. More than half of the patients presented with a mass (28/52, 53.85%), followed by pelvic-dominant pain, discomfort, or fullness (14/52, 26.92%), or their tumors were discovered incidentally during routine checkups or while other unrelated symptoms were being investigated (10/52, 19.23%). More than half of the patients (24/51, 47%) had associated gynecological (12/24, 50%) or non-gynecological (12/24, 50%) disorders. The clinical features of familial adenomatous polyposis were present in 4 patients [9,15,21,22], and 5 patients had a history of malignancy (4 endometrioid endometrial adenocarcinomas, 1 contralateral ovarian endometrioid adenocarcinoma, and 1 colonic adenocarcinoma) [1,6,24]. Tumor markers were evaluated in 19 cases with limited data and undetermined clinical significance; however, an elevation in CA 125 was reported in 4 patients [5,11,14,17].

Ovarian MCSTs are well-circumscribed lesions, and they are usually solid and cystic (29/50, 58%) on macroscopic and/or radiologic examinations. Sonographically, ovarian MCST appears as a hypovascular complex or anechoic cystic mass [14,20]. It is seen as a heterogeneous mass with hyperattenuating and hypoattenuating components on computed tomography scans. Positron emission tomography shows FDG uptake within the solid areas [20]. On MRI, the cystic areas show high-signal intensity on T2-weighted MRI images and iso-signal intensity on T1-weighted images [16].

Microscopically, MCST is a cellular lobulated neoplasm with intervening fibrous, sometimes hyalinized, plaques or bands and, as the name indicates, anastomosing microcysts. The cells are usually monotonous with round to oval nuclei, small nucleoli, and a finely granular pale eosinophilic cytoplasm. Occasionally, the neoplastic cells are spindle-shaped or show a diffuse corded and nested growth pattern either focally, predominantly, or exclusively [24]. Multinucleated cells and cells with bizarre pleomorphic degenerative (sympathetic-like) nuclei can infrequently occur, and the latter can account for up to 50% of the tumor [10,12,18,27]. Mitoses are rare in most cases (0–2 in 10 high-power fields), with no reported atypical forms [10,18]. The stromal nature of ovarian MCST was supported by ultrastructural findings, including the lake of Reinke crystals, true lumina, cilia, microvilli, desmosomes, and cellular junctions [5].

The use of immunohistochemical staining helps differentiate ovarian MCST from its mimickers. The neoplastic cells in MCST show an aberrant nuclear expression for β-catenin and cyclin D1 [1,4–27]. They are usually positive for vimentin, CD10, WT-1, FOXL2, and SF-1 [1,4–27]. Similar to our case, Bi et al reported edematous dot-like staining for CD99 in 3 of the 5 cases examined in their series and progesterone-receptor expression in around 5% of cells in 2 cases [10]. CD56 was reported as positive in 10% of tumor cells in 1 case of ovarian MCST [10]. However, a more diffuse, stronger progesterone-receptor and CD56 staining was displayed in another study [12]. Deng et al reported patchy positive staining for synaptophysin and diffuse positive staining for androgen receptors in 2 cases [24,26]. Reports showed that ovarian MCST is negative for inhibin, calretinin, EMA, E-cadherin, CD117, PLAP, SALL-4, desmin, and mesin A [1,4–27].

The differential diagnosis encompasses a wide range of ovarian tumors. Thecomas usually occur in older women and present with estrogenic effects. They do not show the microcystic pattern of ovarian MCSTs and are positive for calretinin and inhibin [1,11]. Although an ovarian solid pseudopapillary neoplasm (SPN) shows an aberrant β-catenin nuclear expression and CTNNB1 mutations, ovarian MCSTs lack the pseudopapillary pattern and the nuclear grooves that are characteristic of ovarian SPNs. Furthermore, SPN is usually negative for WT-1, diffusely positive for CD56, and can stain for CD117 [28,29]. Ovarian MCST lacks the grooved nuclei and Call-Exner bodies seen in adult granulosa cell tumors. In addition, ovarian MSCTs are negative for calretinin and inhibin and they do not harbor FOXL2 gene mutations [11,18]. Ovarian MCSTs can mimic germ cell tumors, especially yolk sac tumors or metastatic carcinomas, but positive staining for FOXL2 and negative staining for germ cells and epithelial markers exclude these entities.

On a molecular level, essentially all ovarian MCSTs are thought to have heterozygous point mutations in the CTNNB1 gene, or less frequently in the APC gene (Table 1). All reported CTNNB1 mutations were missense mutations [4,7,8,10,11,13,14,17,24].
### Table 1. A summary of all previously published cases of an ovarian microcystic stromal tumor.

| Case | Reference | Age | Molecular findings | Management | Follow-up (months) |
|------|-----------|-----|--------------------|------------|-------------------|
| 1    | Irving and Young, 2009 [1] | 62  | NA                 | TAH, BSO, LND, OM | NA                |
| 2    |           | 45  |                    | TAH, BSO, peritoneal biopsies |                    |
| 3    |           | 51  |                    | TAH, BSO, OM, appendectomy, pelvic washings |                   |
| 4    |           | 29  |                    | LO         |                   |
| 5    |           | 58  |                    | TAH, BSO, LND, peritoneal biopsy, pelvic washings |                   |
| 6    |           | 26  |                    | BSO        |                   |
| 7    |           | 29  |                    | RO         |                   |
| 8    |           | 45  |                    | LSO, endometrial curettage |                   |
| 9    |           | 63  |                    | RO 63      |                   |
| 10   |           | 56  |                    | BSO        |                   |
| 11   |           | 45  |                    | TAH, BSO   |                   |
| 12   |           | 55  |                    | TAH, BSO   |                   |
| 13   |           | 44  |                    | TAH, BSO   |                   |
| 14   |           | 36  |                    | LSO 36     |                   |
| 15   |           | 37  |                    | TAH, BSO   |                   |
| 16   |           | 39  |                    | RSO, pelvic washings |               |
| 17   | Maeda et al, 2011 [4] | 33  | CTNNB1 mutation | 1 GnRHa, RSO, enucleation of uterine masses, partial OM | NED (14) |
| 18   |           | 41  | CTNNB1 mutation | RSO, enucleation of uterine leiomyoma | NED (4) |
| 19   | Yang and Bhattacharjee, 2014 [5] | 45  | NA | Open ovarian tumor resection | NA |
| 20   | Niu and Peng, 2014 [6] | 42  | NA | NA | NA |
| 21   | Irving et al, 2015 [7] | 36  | CTNNB1 mutation | CTNNB1 mutation in 8/14 patients<sup>a</sup> | NA |
| 22   |           | 37  | CTNNB1 wild-type | TAH, BSO | NED (59) |
| 23   |           | 57  | CTNNB1 mutation | TAH, BSO | NED (59) |
| 24   |           | 41  | CTNNB1 wild-type | LO, right ovarian biopsy | NED (18) |
| 25   | Kang et al, 2015 [8] | 41  | CTNNB1 mutation | Laparoscopic LSO | NA |
| 26   | Lee et al, 2015 [9] | 40  | APC mutation | LSO, right ovarian wedge resection, total colectomy | NED (9) |
| 27   | Bi et al, 2015 [10] | 69  | CTNNB1 mutation | LSO | NED (60) |
| 28   |           | 29  | CTNNB1 wild-type | LO, right ovarian biopsy | NED (18) |
| 29   |           | 40  | CTNNB1 mutation | LO | NED (7) |
| 30   |           | 65  | CTNNB1 mutation | TAH, BSO | NA |
| 31   |           | 57  | CTNNB1 mutation | TAH, BSO | NED (59) |
| 32   | Poddukturi et al, 2015 [11] | 41  | CTNNB1 wild-type | TAH, BSO, OM, appendectomy | NED (2) |
| 33   |           | 50  | CTNNB1 mutation | Hysterectomy, BSO, pelvic and para-aortic LND, OM, staging biopsies | NA |
| 34   | Chen et al, 2015 [12] | 47  | NA | LSO | NED (18) |
Table 1 continued. A summary of all previously published cases of an ovarian microcystic stromal tumor.

| Case | Reference | Age | Molecular findings | Management | Follow-up (months) |
|------|-----------|-----|--------------------|------------|-------------------|
| 35   | Gunes et al, 2015 [13] | 52  | CTNNB1 mutation    | TAH, BSO, OM | NED (3)           |
| 36   | Lee et al, 2016 [14] | 24  | CTNNB1 mutation    | Laparoscopic LSO | NED (8) |
| 37   | Liu et al, 2016 [15] | 23  | APC mutation       | Laparoscopic hysterectomy, RO, BS | NA |
| 38   | Murakami et al, 2017 [16] | 26  | CTNNB1 wild-type   | 4 GnRHa, LSO | NED (36)          |
| 39   | Na et al, 2017 [17] | 33  | CTNNB1 mutation    | Laparoscopic RSO, partial OM | NED (57) |
| 40   | Meurgey et al, 2017 [18] | 46  | FOXL2 and DICER1 wild-types | 2 LSO, 1 RSO | NA |
| 41   | Qureshi et al, 2017 [19] | 50  | NA                | LO         | NA                |
| 42   | Jeong et al, 2018 [20] | 66  | NA                | BSO, bilateral pelvic and para-aortic LND, infra-colic OM, peritoneal biopsies | NED (18) |
| 43   | Zhang et al, 2018 [21] | 33  | APC mutation      | Right laparoscopic cystectomy | Intraovarian and extraovarian recurrence (108) |
| 44   | Hasanzadeh et al, 2019 [23] | 60  | NA                | TAH, BSO   | NED (15)          |
| 45   | McCluggage et al, 2019 [24] | 61  | CTNNB1 mutation    | BSO        | NA                |
| 46   | Liu et al, 2019 [25] | 46  | NA                | Laparoscopic RSO | NED (54) |
| 47   | Deng et al, 2020 [26] | 25  | NA                | Laparoscopic resection of ovarian tumor | NED (4) |
| 48   | He et al, 2020 [27] | 33  | NA                | Laparoscopic resection of ovarian tumor | NED (19) |
| 49   | Current case | 46  | CTNNB1 mutation    | Open LSO, infra-colic OM, bilateral peritoneal biopsies, left pelvic LND, appendectomy | NED (24) |

a Follow-up data were available for 7 patients with no evidence of disease after a mean period of 51 months. b The study evaluated 15 patients; 11 were included in Irving et al, 2009 and 4 were additional cases. c In 2017, the cases were re-examined by McCluggage et al for APC mutations. Two cases were initially reported to have CTNNB1 wild-type showed CTNNB1 mutations and 3 cases showed APC mutations including the patient with FAP.

BEMP – benign endometrial polyp; BS – bilateral salpingectomy; BSO – bilateral salpingo-oophorectomy; EEA – endometrioid endometrial adenocarcinoma; FAP – familial adenomatous polyposis; GnRHa – gonadotropic releasing hormone analog; LND – lymph nodes dissection; LO – left oophorectomy; LSO – left salpingo-oophorectomy; NA – not available; NED – no evidence of disease; OM – omentectomy; RO – right oophorectomy; RSO – right salpingo-oophorectomy; TAH – total abdominal hysterectomy.
except for 1 case, which was a deletion mutation [17]. APC mutations were present in 5 cases [9,15,21,22]. CTNNB1 gene encodes the multifunctional β-catenin protein, an adherence junction protein and a transcription regulator, in the Wnt signaling pathway. In the absence of Wnt stimulation, β-catenin remains in the cytoplasm and undergoes phosphorylation and death by the axin-APC complex [15,30]. When Wnt binds to its receptor, the axin-APC complex is inactivated, and β-catenin accumulates in the cytoplasm and eventually translocates to the nucleus to initiate DNA transcription [15,30]. Thus, mutations in the Wnt/β-catenin pathway genes (eg, CTNNB1 or APC) result in an aberrant nuclear immunoreactivity for β-catenin protein, although this expression does not always correlate with β-catenin mutations [10].

Ovarian MCST was treated surgically in a total of 36 patients (66.67%) undergoing oophorectomy (with or without salpingectomy) or cystectomy and 18 patients undergoing hysterectomy (including bilateral or unilateral salpingo-oophorectomy) with or without omentectomy, lymph node dissection, or appendectomy (33.33%) (Table 1). Two patients received gonadotropin-releasing hormone analog injections but showed tumor size progression and eventually underwent unilateral salpingo-oophorectomy [4,16].

Lymph node dissection is not mandatory in cases of sex cord-stromal tumors and germ cell tumors. The lymph nodes in our patient were not palpable bilaterally, and they were not suspicious radiologically; however, since the diagnosis was not confirmed during the surgery, an ipsilateral lymph node dissection was performed. If lymph nodes are involved with a sex cord-stromal tumor or germ cell tumor, chemotherapy would be indicated, regardless of the status of the contralateral lymph nodes. An appendectomy, although it may not have been necessary, was performed in our patient because an epithelial mucinous tumor was still among the radiological differential diagnoses.

Regardless of the chosen surgical management, all reported cases of ovarian MCST showed a good prognosis and uneventful outcomes (mean follow-up of 26.45 months), except for 1 patient who presented with a recurrence 9 years after her initial diagnosis [21]. The literature is limited regarding the optimal follow-up approach for these patients; however, we recommend annual pelvic ultrasound screening, followed by MRI if indicated.

**Conclusions**

We described a case of ovarian MCST and outlined the clinical, radiological, and pathological features of this tumor in view of all the reported cases in the literature. This tumor should be considered when there is presentation of cystic ovarian tumors. Furthermore, the present data provide insight into this tumor and encourage further research into its pathogenesis, behavior, treatment, and long-term prognosis.

**Declaration of Figures’ Authenticity**

All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.

**References:**

1. Irving JA, Young RH. Microcystic stromal tumor of the ovary: Report of 16 cases of a hitherto uncharacterized distinctive ovarian neoplasm. Am J Surg Pathol. 2009;33(3):367-75
2. Kurman R, Carcangiu M, Herrington C, Young R, eds. World Health Organization Classification of Tumours of Female Reproductive Organs. 4th ed. Geneva: International Agency for Research on Cancer; 2014
3. World Health Organization Classification of Tumours Editorial Board, ed. Female Genital Tumours. 5th ed. Geneva: International Agency for Research on Cancer; 2020
4. Maeda D, Shibahara J, Sakuma T, et al. β-catenin (CTNNB1) S33C mutation in ovarian microcystic stromal tumors. Am J Surg Pathol. 2011;35(10):1429-40
5. Yang M, Bhattacharjee MB. Ovarian microcystic stromal tumor: Report of a new entity with immunohistochemical and ultrastructural studies. Ultrastruct Pathol. 2014;38(4):261-67
6. Niu S, Peng Y. Distinct immunophenotypic features of ovarian microcystic stromal tumor. Am J Clin Pathol. 2014;142:A239
7. Irving JA, Lee C-H, Yip S, et al. Microcystic stromal tumor: A distinctive ovarian sex cord-stromal neoplasm characterized by FOXL2, SF-1, WT-1, Cyclin D1, and β-catenin nuclear expression and CTNNB1 mutations. Am J Surg Pathol. 2015;39(10):1420-26
8. Kang YN, Cho CH, Kwon SY. Microcystic stromal tumor of the ovary with mutation in exon 3 of β-catenin. A case report. Int J Gynecol Pathol. 2015;34(2):121-25
9. Lee SH, Koh YW, Roh HJ, et al. Ovarian microcystic stromal tumor: A novel extracolonic tumor in familial adenomatous polyposis. Genes Chromosomes Cancer. 2015;54(6):353-60
10. Bi R, Bai Q-M, Yang F, et al. Microcystic stromal tumor of the ovary: Frequent mutations of β-catenin (CTNNB1) in six cases. Histopathology. 2015;67(6):872-79
11. Podduturi V, Tran T, Champion KJ, et al. Microcystic stromal tumor of the ovary: A case report of a newly described ovarian neoplasm with β-catenin (CTNNB1) G34E mutation. Int J Gynecol Pathol. 2015;34(6):541-45
12. Chen Q, Lu W, Lv W. Overlap of microcystic stromal tumor and primary solid pseudopapillary neoplasm of the ovary. Int J Clin Exp Pathol. 2015;8(9):11792-97
13. Gunes P, Kir G, Yilmaz I, Küçükodaci Z. Coexistence of microcystic stromal tumor and extracolonic tumor in familial adenomatous polyposis. Genes Chromosomes Cancer. 2016;55(6):546-50
14. Lee JH, Kim H-S, Cho NH, et al. Genetic analysis of ovarian microcystic stromal tumor and its relation with extracolonic tumor. Int J Gynecol Pathol. 2016;35(6):561-65
15. Liu C, Gallagher RL, Price GR, et al. Ovarian microcystic stromal tumor: A rare clinical manifestation of familial adenomatous polyposis. Int J Gynecol Pathol. 2016;35(6):561-65
16. Murakami M, Wroblewski J, Kawagoe H. Microcystic stromal tumor resected by laparoscopic surgery. Gynecol Minim Invasive Ther. 2017;6(3):135-18

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
17. Na K, Kim EK, Jang W, Kim H-S. CTNNB1 mutations in ovarian microcystic stromal tumors: Identification of a novel deletion mutation and the use of pyrosequencing to identify reported point mutation. Anticancer Res. 2017;37(6):3249-58

18. Meurgey A, Descotes F, Mery-Lamarche E, Devouassoux-Shisheboran M. Lack of mutation of DICER1 and FOXL2 genes in microcystic stromal tumor of the ovary. Virchows Arch. 2017;470(2):225-29

19. Qureshi A, Hassan M, Mamoon N, et al. Sex cord stromal tumours of the ovary, experience at Shifa International Hospital Islamabad. J Pak Med Assoc. 2017;67(7):1107-8

20. Jeong D, Hakam A, Abuел-Haija M, Chon HS. Ovarian microcystic stromal tumor: Radiologic-pathologic correlation. Gynecol Oncol Rep. 2018;25:11-14

21. Zhang Y, Tao L, Yin C, et al. Ovarian microcystic stromal tumor with undetermined potential: Case study with molecular analysis and literature review. Hum Pathol. 2018;78:171-76

22. McCluggage WG, Irving JA, Chong A-S, et al. Ovarian microcystic stromal tumors are characterized by alterations in the beta-catenin-APC pathway and may be an extracolonic manifestation of familial adenomatous polyposis. Am J Surg Pathol. 2018;42(1):137-39

23. Hasanzadeh M, Bazmi F, Malakuti P. An ovarian mass with microcystic stromal tumor: A rare case report. J Obstet Gynecol Cancer Res. 2019;6(3):127-30

24. McCluggage WG, Chong A-S, Attygalle AD, et al. Expanding the morphological spectrum of ovarian microcystic stromal tumour. Histopathology. 2019;74(3):443-51

25. Liu J, Hou Y, Bao L, et al. Ovarian microcystic stromal tumors: Clinical, radiological, and pathological studies of two cases. Int J Clin Exp Pathol. 2019;12(6):2241-48

26. Deng L, Feng D, Liang J, et al. Ovarian microcystic stromal tumor: A case report and literature review. Front Med (Lausanne). 2020;7:58

27. He Y, Xu L, Feng M, Wang W. Ovarian microcystic stromal tumor with significant bizarre nuclei: A case report. Medicine (Baltimore). 2020;99(34):e21841

28. Cheuk W, Beavon I, Chui DTY, Chan JK. Extrapancreatic solid pseudopapillary neoplasm: Report of a case of primary ovarian origin and review of the literature. Int J Gynecol Pathol. 2011;30(6):539-43

29. Deshpande V, Oliva E, Young RH. Solid pseudopapillary neoplasm of the ovary: A report of 3 primary ovarian tumors resembling those of the pancreas. Am J Surg Pathol. 2010;34(10):1514-20

30. Rabban JT, Kamezis AN, Devine WP. Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics. Histopathology. 2020;76(1):11-24